Send us a text

In this episode of our WTR Small Cap Spotlight, we sat down with LifeVantage (NASDAQ: LFVN ) CEO Steve Fife and CMO Julie Boyster to drill down on the science of nutrigenomics, which is the study of how nutrients impact our genes, and how LifeVantage’s proprietary formulations of naturally found ingredients work together to activate genes and help improve overall health and wellbeing.  Recent clinical studies further demonstrate the efficacy of the company’s new patent-pending MindBody GLP-1 System, and the company discusses additional synergistic benefits from combining MindBody with the company’s flagship Nrf2 Synergizer.   

Send us a text

In this special edition of the WTR Small-Cap Spotlight Flashcast, host Tim Gerdeman sits down with Chris Degner, Managing Director in Water Tower Research’s Energy Practice, to explore major shifts in the oil and natural gas markets. The discussion covers rising OPEC production, evolving global supply structures, and a deep dive into LNG market trends—including emerging export projects in the U.S. and Australia. The episode also spotlights Tamboran Resources, a small-cap company with high-potential natural gas assets in Australia. Tune in for expert insights on where the energy markets are headed and what it means for small-cap investors. 

Send us a text

In this 2nd episode or our two-part WTR Symposium Series podcast, "NEXT-GEN VEHICLES: Investing in Small Drones and Unmanned Vehicles", senior management of Arrive AI (ARAI), Nauticus Robotics (KITT), Ocean Power Technologies (OPTT), and Palladyne AI (PDYN) join the Water Tower Research team including Founding Partner and CEO, Shawn Severson, Managing Director - Energy Transition and Sustainable Investing, Peter Gastreich, and Managing Director - Technology, Dr. John Roy. These companies are high-growth and with innovative unmanned vehicle solutions focused on improving efficiency and safety for industries as diverse as offshore oil & gas, subsea mining, offshore wind energy, pipelines, defense, surface logistics, and CO2 sequestration.

Send us a text

In our latest WTR-Small-Cap Spotlight podcast, we were joined by Jack Lu,  Director of corporate Development at Ainos (NASDAQ: AIMD) to discuss the company's pioneering smell digitization AI technology platform, AI Nose; diversification of the platform's penetration across multiple verticals through strategic partnerships;  commercialization opportunities and expansion goals.

Send us a text

In this episode of WTR Small-Cap x Healthcare Spotlight crossover episode, we are joined by Lisata Therapeutics' (NASDAQ: LSTA) CEO David Mazzo, PhD and Chief Medical Officer Kristen Buck, MD to talk about, Certepetide, the company's novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties.  We also dive into the recently reported positive preliminary results from Lisata's lead program (Ascend), a Phase 2b study investigating Certepetide for metastatic pancreatic ductal adenocarcinoma (the most common and aggressive form of pancreatic cancer), Lisata's partnerships, and upcoming milestones.  

Send us a text

In this two-part WTR Symposium Series podcast, "NEXT-GEN VEHICLES: Investing in Small Drones and Unmanned Vehicles", management of Micropolis Holding Company (MCRP), Ondas Holdings Inc. (ONDS), SES AI Corp, (SES) and Unusual Machines, Inc. (UMAC) join the Water Tower Research team including Founding Partner and CEO, Shawn Severson and Managing Director - Technology, Dr. John Roy. Drones are everywhere and stocks are moving up. Hear what 4 CEOs in the drone industry are saying about investing, consolidation, and the need for standards. 

Stay tuned next week for part-two with WTR's Peter Gastreich!

Send us a text

In our latest WTR Small-Cap Spotlight x Healthcare Crossover, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscape

Cybin (NYSE: CYBN) is a late-stage clinical development company focused on developing novel psychedelic-based neuropsychiatric compounds. Its two lead candidates, targeting two of the most pervasive mental health disorders, are psilocin-based CYB003 for Major Depressive Disorder (MDD), currently being dosed in a Phase 3 program, and DMT-based CYB004 for General Anxiety Disorder (GAD) which is wrapping up a Phase 2 study.  

Send us a text

On this week's episode of the WTR Small-Cap Spotlight, Nir Brenmiller, Chief Operating Officer, Co-Founder and Director at Brenmiller Energy (NASDAQ ticker BNRG), joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainable Investing Analyst at Water Tower Research to discuss: 1) the company’s innovative heat storage technology that bridges the intermittency of renewable energy generation and provides clean energy in the form of steam to industrial and other customers; 2) the multi-trillion dollar market opportunity for decarbonization of heat and electrification of heat; 3) what makes the technology competitive and lower cost when compared to traditional boilers and natural gas; 4) the company’s “heat as a service” business model targeting leading corporations looking to decarbonize; and 5) the first flagship operations starting by the end of this year plus a $500 million pipeline.

Send us a text

In Part 2 of our WTR Small-Cap Spotlight Executive Series with SurgePays (NASDAQ: SURG), we continue our conversation with President Derron Winfrey—shifting focus from the company’s mobile virtual network enabler (MVNE) platform to its flagship mobile virtual network operator (MVNO) business, LinkUp Mobile. This episode explores how SurgePays is expanding affordable wireless access through its prepaid service model and what sets LinkUp apart in a competitive market. 

Send us a text

In this episode of the WTR Small-Cap | Biotech Spotlight Crossover, Water Tower Research’s Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company’s pioneering work in neuroplastogen drug development and delivery technologies.

Dr. Chris  Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape.

Tune in to learn more about Psilera’s vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.